13 research outputs found
X-Linked Lymphoproliferative Disease Type 1: A Clinical and Molecular Perspective
X-linked lymphoproliferative disease (XLP) was first described in the 1970s as a fatal
lymphoproliferative syndrome associated with infection with Epstein–Barr virus (EBV).
Features include hemophagocytic lymphohistiocytosis (HLH), lymphomas, and dysgammaglobulinemias.
Molecular cloning of the causative gene, SH2D1A, has provided
insight into the nature of disease, as well as helped characterize multiple features of
normal immune cell function. Although XLP type 1 (XLP1) provides an example of a
primary immunodeficiency in which patients have problems clearing primarily one infectious
agent, it is clear that XLP1 is also a disease of severe immune dysregulation, even
independent of EBV infection. Here, we describe clinical features of XLP1, how molecular
and biological studies of the gene product, SAP, and the associated signaling lymphocyte
activation molecule family receptors have provided insight into disease pathogenesis
including specific immune cell defects, and current therapeutic approaches including the
potential use of gene therapy. Together, these studies have helped change the outcome
of this once almost uniformly fatal disease
The EuroFlow PID Orientation Tube for Flow Cytometric Diagnostic Screening of Primary Immunodeficiencies of the Lymphoid System
In the rapidly evolving field of primary immunodeficiencies (PID), the EuroFlow consortium decided to develop a PID orientation and screening tube that facilitates fast, standardized, and validated immunophenotypic diagnosis of lymphoid PID, and allows full exchange of data between centers. Our aim was to develop a tool that would be universal for all lymphoid PIDs and offer high sensitivity to identify a lymphoid PID (without a need for specificity to diagnose particular PID) and to guide and prioritize further diagnostic modalities and clinical management. The tube composition has been defined in a stepwise manner through several cycles of design-testing-evaluation-redesign in a multicenter setting. Equally important appeared to be the standardized pre-analytical procedures (sample preparation and instrument setup), analytical procedures (immunostaining and data acquisition), the software analysis (a multidimensional view based on a reference database in Infinicyt software), and data interpretation. This standardized EuroFlow concept has been tested on 250 healthy controls and 99 PID patients with defined genetic defects. In addition, an application of new EuroFlow software tools with multidimensional pattern recognition was designed with inclusion of maturation pathways in multidimensional patterns (APS plots). The major advantage of the EuroFlow approach is that data can be fully exchanged between different laboratories in any country of the world, which is especially of interest for the PID field, with generally low numbers of cases per center